[go: up one dir, main page]

WO2003102235A3 - Specific genetic markets for cytogenetically defined acute myeloid leukaemia - Google Patents

Specific genetic markets for cytogenetically defined acute myeloid leukaemia Download PDF

Info

Publication number
WO2003102235A3
WO2003102235A3 PCT/GB2003/002315 GB0302315W WO03102235A3 WO 2003102235 A3 WO2003102235 A3 WO 2003102235A3 GB 0302315 W GB0302315 W GB 0302315W WO 03102235 A3 WO03102235 A3 WO 03102235A3
Authority
WO
WIPO (PCT)
Prior art keywords
sample
acute myeloid
aml
myeloid leukaemia
patient
Prior art date
Application number
PCT/GB2003/002315
Other languages
French (fr)
Other versions
WO2003102235A2 (en
Inventor
Bryan Douglas Young
Silvana Debernardi
Simon Roy Tomlinson
Original Assignee
Cancer Rec Tech Ltd
Bryan Douglas Young
Silvana Debernardi
Simon Roy Tomlinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Bryan Douglas Young, Silvana Debernardi, Simon Roy Tomlinson filed Critical Cancer Rec Tech Ltd
Priority to AU2003234035A priority Critical patent/AU2003234035A1/en
Publication of WO2003102235A2 publication Critical patent/WO2003102235A2/en
Publication of WO2003102235A3 publication Critical patent/WO2003102235A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of assigning a patient having or suspected of having acute myeloid leukaemia (AML) to a cytogenetically defined AML class, the method comprising providing a sample from the patient, using gene expression profiling to determine the expression level of at least one informative gene in the sample, and using the at least one determined expression level to assign the sample to an AML class. The invention also includes a method of assigning a patient having or suspected of having AML to an AML class, comprising providing a sample from the patient, determining the expression level of at least one informative gene selected from the genes listed in Table 1 or Table 2 or Table 3 in the sample, and using the at least one determined expression level to assign the sample to an AML class.
PCT/GB2003/002315 2002-05-31 2003-05-28 Specific genetic markets for cytogenetically defined acute myeloid leukaemia WO2003102235A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003234035A AU2003234035A1 (en) 2002-05-31 2003-05-28 Specific genetic markets for cytogenetically defined acute myeloid leukaemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38506502P 2002-05-31 2002-05-31
US60/385,065 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003102235A2 WO2003102235A2 (en) 2003-12-11
WO2003102235A3 true WO2003102235A3 (en) 2004-06-17

Family

ID=29712131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002315 WO2003102235A2 (en) 2002-05-31 2003-05-28 Specific genetic markets for cytogenetically defined acute myeloid leukaemia

Country Status (2)

Country Link
AU (1) AU2003234035A1 (en)
WO (1) WO2003102235A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723257B1 (en) * 2004-02-23 2019-01-09 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
BRPI0607753A2 (en) * 2005-02-16 2009-10-06 Wyeth Corp method for predicting a clinical effect in response to a treatment of a leukemia; method for predicting a clinical effect of a leukemia; method for selecting a treatment for a leukemia patient; method for the diagnosis or monitoring of the occurrence, development, progression or treatment of a leukemia; arrangement for use in a method for predicting a clinical effect for an aml patient; arrangement for use in an aml diagnostic method; computer readable medium; aml prognosis kit
WO2006119494A2 (en) * 2005-05-04 2006-11-09 Exagen Diagnostics, Inc. Acute myelogenous leukemia biomarkers
CN113136432A (en) * 2021-05-06 2021-07-20 杭州艾迪康医学检验中心有限公司 Reagent and method for detecting relative expression quantity of PRAME gene in AML

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633136A (en) * 1991-12-11 1997-05-27 Thomas Jefferson University ALL-1 polynucleotides for leukemia detection and treatment
WO2000055180A2 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1308522A1 (en) * 2001-11-05 2003-05-07 Haferlach, Torsten, PD Dr. Dr. Novel genetic markers for leukemias

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633136A (en) * 1991-12-11 1997-05-27 Thomas Jefferson University ALL-1 polynucleotides for leukemia detection and treatment
WO2000055180A2 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1308522A1 (en) * 2001-11-05 2003-05-07 Haferlach, Torsten, PD Dr. Dr. Novel genetic markers for leukemias

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEBANK [online] 12 September 1993 (1993-09-12), BRAUN ET AL.: "Human RNA mitochondrial aldehyde dehydrogenase I ALDH I", XP002252495, Database accession no. X05409 *
KOHLMANN ALEXANDER ET AL: "U937 cell line transfected with Zinc-inducible PML-RARalpha is a suitable model system for acute promyelocytic leukemia: A comparison of gene expression profiles in cell lines and clinical samples.", BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 2;Orlando, Florida, USA; December 07-11, 2001, November 16, 2001, pages 160b - 161b, XP001160824, ISSN: 0006-4971 *
PABST ET AL.: "AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia", NATURE MEDICINE, vol. 7, no. 4, April 2001 (2001-04-01), pages 444 - 451, XP002255850 *
VIRTANEVA K ET AL: "EXPRESSION PROFILING REVEALS FUNDAMENTAL BIOLOGICAL DIFFERENCES IN ACUTE MYELOID LEUKEMIA WITH ISOLATED TRISOMY 8 AND NORMAL CYTOGENETICS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 1124 - 1129, XP002952627, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003102235A2 (en) 2003-12-11
AU2003234035A8 (en) 2003-12-19
AU2003234035A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
EP2230319A3 (en) Gene expression markers for breast cancer prognosis
WO2006023769A3 (en) Determining data quality and/or segmental aneusomy using a computer system
GB2409455A (en) Parallel loading of arrays
EP2418544A3 (en) Method and system for determining characteristics of substrates employing fluid geometries
EP2468890A3 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
HK1049515B (en) Methods of using randomized libraries of zinc finger proteins for the identification of gene function
GB2407902A (en) Gaming device having an award level determination competition
HUP0101039A2 (en) Terminal for processing digital audiovisual or multimedia data, further method of actuating this terminal
MA29941B1 (en) IMPROVED TESTOSTERONE GEL AND METHOD OF USE
MXPA03004913A (en) Uses of mammalian genes and related reagents.
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
ATE336591T1 (en) DETECTION METHODS FOR SHORT SEQUENCE VARIANTS
SI1454992T1 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005045725A3 (en) Determining a location for placing data in a spreadsheet based on a location of the data source
WO2003102235A3 (en) Specific genetic markets for cytogenetically defined acute myeloid leukaemia
EP2249155A3 (en) Cancer markers
ATE191012T1 (en) SCINTILLATION PROXIMITY TEST FOR N-ACETYLGALACTOSAMINYL TRANSFERASE ACTIVITY
WO2005007097A3 (en) Breast cancer genes
ATE256120T1 (en) REAGENTS FOR CYP2D FLUORESCENCE TEST
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling
GB2412968A (en) Method of harmonic noise attenuation in correlated sweep data
EP1285970A3 (en) Metastasis-associated genes
GB0617116D0 (en) Method of diagnosis
HK1063338A1 (en) Quantitative diagnostic analysis of hypertonia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP